Experimental enzyme treatment protects mice from lethal anthrax infection
All mice infected with anthrax spores were completely protected after treatment with a pegylated enzyme known as PEG-CapD-CPS334C.
List view / Grid view
All mice infected with anthrax spores were completely protected after treatment with a pegylated enzyme known as PEG-CapD-CPS334C.
The new study used cryo-electron microscopy to visualise the structure of a HAT protein and uncover compounds for drug development.
A new study prevented the growth of metastatic tumours in mice by forcing cancer cells into a dormant state, pointing to novel treatments.
A new study links tumour necrosis factor seen in rheumatoid arthritis with T cell dysfunction, potentially leading to new therapies.
The antihypertensive drug candesartan cilexetil reduced matrisomal protein accumulation in mice with cerebral small vessel disease.
An experimental drug for liver cancer and Dasatinib, approved for chronic myeloid leukaemia could be repurposed to treat Alzheimer's disease.
The study paves the way for the construction of complex nanoscale computers for the prevention and treatment of cancer and other diseases.
Scientists targeted a mouse's own cells using a synthetic molecule called EEZE, presenting a novel way to treat pneumonia.
Researchers used advanced microscopy and proteomics to unveil new findings on Huntington's disease and open avenues to future treatments.
A new study claims that future COVID-19 vaccines should activate T cells to attack infected cells expressing replication proteins.
The intestine chip was infected with a coronavirus to test a variety of drugs, presenting a new method to investigate COVID-19 treatments.
In a pre-clinical study, fibrinogen increased the death of mouse brain neurons, suggeting fibrin can have similar toxic effects on neurons.
The absence of interleukin-36 receptor antagonist (IL-36Ra) significantly slowed down wound healing in ischemia-reperfusion injuries in mice.
Scientists revealed five proteins that cause blood vessel damage in COVID-19 patients, potentially leading to new drug targets.
Turning off NHE6 in mice in pre-clinical studies prevented amyloid beta aggregation, a key feature of Alzheimer's disease, pointing to new therapies.